Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$4.33 – $5.71
97% from low
No one on the platform currently holds SCPH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 58,656 | $267.5K |
No one on the platform has traded SCPH yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $128M | +76.1% | $-0.16 | $-0.45–$0.20 | — | 3 |
| 2027 | $186M | +45.4% | $0.67 | $0.28–$1.50 | 8.5× | 4 |
| 2028 | $242M | +29.8% | $1.27 | $1.14–$1.39 | 4.5× | 2 |
| 2029 | $296M | +22.3% | $1.82 | $1.63–$1.99 | 3.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-11-12 | $-0.25 | $-0.37 | -48.0% |
| 2025-08-07 | $-0.30 | $-0.34 | -13.3% |
| 2025-05-14 | $-0.27 | $-0.34 | -25.9% |
| 2025-03-19 | $-0.40 | $-0.35 | +12.5% |
| 2024-11-13 | $-0.30 | $-0.37 | -23.3% |
| 2024-08-14 | $-0.44 | $-0.44 | +0.0% |
| 2024-05-14 | $-0.45 | $-0.36 | +20.0% |
| 2024-03-13 | $-0.42 |
| $-0.35 |
| +16.7% |
| $302M |
| — |
| ORTXOrchard Therapeutics plc | $16.70 | +0.30% | $380M | — |
| SLRNAcelyrin, Inc. | $2.27 | +0.00% | $229M | — |
Source: Financial Modeling Prep · peers by sector/industry
$MNKD When there's somethin' strange in the neighborhood. Who ya' gonna call? Lasagna. $UTHR $BX $SCPH
View on StockTwits ↗$MNKD The first $200,000,000 of PROFIT that Mannkind makes from its scPharma division ... will be tax-free! 🤑 @DRFSR So they got that goin' for it, which is nice. 💲 $SCPH 👍 $SPY 💲
View on StockTwits ↗$MNKD Here's why hype and exuberance around Mannkind's progress will likely propel MNKD to over $50/sh by the end of 2028... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $1 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approved Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $8 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug -------- +$48/sh Take a 👀 🫵 $SPY and $QQQ 🤑
View on StockTwits ↗$SCPH anyone tracking SCPH product sales at $MNKD? Are they going to have to pay us the additional $0.25/share? SCPH product sales need to exceed $120MM in 2026 to trigger the additional payment.
View on StockTwits ↗APPROVALS {and eventual accretive} ADDS TO $MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $2 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approval of Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $7 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug -------- +$48/sh
View on StockTwits ↗$SCPH $0.75/share coming our way! https://mannkindcorp.com/furoscixnews/
View on StockTwits ↗Another takeaway from $SCPH & a few others in the past year for that matter $DAWN $APLS $SLNO Forced selling taking place before buyout on the cheap (need an artificially high premium) $XBI
View on StockTwits ↗$MNKD (NP) Furoscix autoinjector approved (snagged from $SCPH on cheap buyout, final trade chart from that one below) Set price alerts at $3.50 in case it pulls back (should see nice multi-year revenue ramp & perhaps additional tech partnerships, not only with $UTHR) Nintedanib in IPF not be overlooked either IMO
View on StockTwits ↗$SCPH what was the additional payout for approval of the auto injector and when will it be paid out?
View on StockTwits ↗$RCEL I sincerely believe this is a takeover target, similar to how $SCPH was a takeover target last year. They are burning cash, but also starting to show meaningful signs of growth, in my opinion. I can see this going to $10+ if earnings are excellent, and I believe a $600M valuation is not crazy if all goes amazingly well. Having said that, I anticipate that they will raise capital shortly after Q2 ER next month, so I understand that can influence the valuation if dilution is involved, which seems like a reasonable (and arguably likely) possibility based on management's language after the Q1 ER. If they don't raise cash shortly after, perhaps they are open to a sale of the company. I would love to see $20 per share by end of this year. This is purely speculation on my part, though. Always do your own research and due diligence. Please fact check my post in case I got anything wrong.
View on StockTwits ↗$MNKD Mannkind acquiring SCPharma $SCPH and folding it in as a division of Mannkind, and operating as is, allows Mannkind to use SCPharma's ~$200,000,000 in capital loss carryforewards against coming Earnings/Profits as offsets to negate what would have been tax burdens. Huge! Benefit! Huge!
View on StockTwits ↗$MNKD Mannkind with an advancing, productive, and prosperous pipeline... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $2 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approval of Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $7 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug 👈👀😲🤑 -------- +$48/sh $SPY 👀 🇺🇲💪
View on StockTwits ↗$SPCX $SCPH $SSPC these could have a lil rebound if INDICES behave tomm
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.